GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

aceclidine   Click here for help

GtoPdb Ligand ID: 14102

Synonyms: ±aceclidine | LINZ-101 | LINZ101 | racemic aceclidine | VIZZ®
Approved drug
aceclidine is an approved drug
Compound class: Synthetic organic
Comment: The INN aceclidine refers to the racemic mixture of (-)-aceclidine and (+)-aceclidine. We represent this here with the 'flat' structure. Aceclidine is an agonist at muscarinic acetylcholine GPCRs.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 2
Topological polar surface area 29.54
Molecular weight 169.22
XLogP 0.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(=O)OC1CN2CCC1CC2
Isomeric SMILES CC(=O)OC1CN2CCC1CC2
InChI InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
InChI Key WRJPSSPFHGNBMG-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
An opthalmic soution containing racemic aceclidine hydrochloride was approved by the US FDA to treat presbyopia (31st July 2025).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
When applied topically to the eye, aceclidine activates muscarinic receptors located on smooth muscles of the iris sphincter, causing contraction of the pupil. This improves vision by extending depth of focus.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05656027 Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia Phase 3 Interventional LENZ Therapeutics, Inc
NCT05753189 Phase 3 Safety Study for the Treatment of Presbyopia Subjects Phase 3 Interventional LENZ Therapeutics, Inc
NCT05728944 Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia Phase 3 Interventional LENZ Therapeutics, Inc